Your browser doesn't support javascript.
loading
Metabolic characterization of hypertrophic cardiomyopathy in human heart.
Wang, Wenmin; Wang, Jizheng; Yao, Ke; Wang, Shuiyun; Nie, Meng; Zhao, Yizi; Wang, Bohong; Pang, Huanhuan; Xu, Jingjing; Wu, Guixin; Lu, Minjie; Tang, Nan; Qi, Chunmei; Pei, Hengzhi; Luo, Xufang; Li, Dongsheng; Yang, Tianshu; Sun, Qing; Wei, Xiang; Li, Yan; Jiang, Dingsheng; Li, Peng; Song, Lei; Hu, Zeping.
Afiliação
  • Wang W; School of Pharmaceutical Sciences, Tsinghua-Peking Center for Life Sciences, Beijing Frontier Research Center for Biological Structure, Tsinghua University, Beijing, China.
  • Wang J; Shanghai Qi Zhi Institute, Shanghai, China.
  • Yao K; State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. jzwang@hotmail.com.
  • Wang S; School of Pharmaceutical Sciences, Tsinghua-Peking Center for Life Sciences, Beijing Frontier Research Center for Biological Structure, Tsinghua University, Beijing, China.
  • Nie M; Shanghai Qi Zhi Institute, Shanghai, China.
  • Zhao Y; Department of Cardiac Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Wang B; School of Pharmaceutical Sciences, Tsinghua-Peking Center for Life Sciences, Beijing Frontier Research Center for Biological Structure, Tsinghua University, Beijing, China.
  • Pang H; School of Pharmaceutical Sciences, Tsinghua-Peking Center for Life Sciences, Beijing Frontier Research Center for Biological Structure, Tsinghua University, Beijing, China.
  • Xu J; Shanghai Qi Zhi Institute, Shanghai, China.
  • Wu G; School of Pharmaceutical Sciences, Tsinghua-Peking Center for Life Sciences, Beijing Frontier Research Center for Biological Structure, Tsinghua University, Beijing, China.
  • Lu M; School of Pharmaceutical Sciences, Tsinghua-Peking Center for Life Sciences, Beijing Frontier Research Center for Biological Structure, Tsinghua University, Beijing, China.
  • Tang N; Waters Corporation (China), Beijing, China.
  • Qi C; State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Pei H; Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Luo X; State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Li D; The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
  • Yang T; The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
  • Sun Q; School of Computer Science, University of Illinois Urbana Champaign, Champaign, IL, USA.
  • Wei X; Microsoft Research Asia, Shanghai, China.
  • Li Y; Microsoft Research Asia, Shanghai, China.
  • Jiang D; Shanghai Qi Zhi Institute, Shanghai, China.
  • Li P; Institute of Metabolism and Integrative Biology, Fudan University, Shanghai, China.
  • Song L; Institute of Biophysics, Chinese Academy of Science, Beijing, China.
  • Hu Z; Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Nat Cardiovasc Res ; 1(5): 445-461, 2022 May.
Article em En | MEDLINE | ID: mdl-39195941
ABSTRACT
Hypertrophic cardiomyopathy (HCM) is a common inherited cardiovascular disease with heterogeneous clinical presentations, governed by multiple molecular mechanisms. Metabolic perturbations underlie most cardiovascular diseases; however, the metabolic alterations and their function in HCM are unknown. Here, we describe the metabolome and lipidome of heart and plasma samples from individuals with and without HCM. Correlation analyses showed strong association between metabolic alterations and cardiac function and prognosis of patients with HCM. Using machine learning we identified metabolite panels as potential HCM diagnostic markers or predictors of survival. Clustering based on metabolome and lipidome of heart enabled stratification of patients with HCM into three subgroups with distinct cardiac function and survival. Integration of metabolomics and proteomics data identified metabolic pathways significantly altered in patients with HCM, with the pentose phosphate pathway and oxidative stress being particularly upregulated. Thus, targeting the pentose phosphate pathway and oxidative stress may serve as potential therapeutic strategies for HCM.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article